Further to its bulletin dated July 9, 2026, the Toronto Stock Exchange reports that it has extended its review of the eligibility of Appili Therapeutics Inc.'s Class A common shares for continued listing for a period of 30 days.
© 2026 Canjex Publishing Ltd. All rights reserved.